Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 188

1.

PCSK9 inhibition: the next statin?

Vogel RA.

J Am Coll Cardiol. 2012 Jun 19;59(25):2354-5. doi: 10.1016/j.jacc.2012.03.011. Epub 2012 Mar 31. No abstract available.

2.

Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy.

McKenney JM, Koren MJ, Kereiakes DJ, Hanotin C, Ferrand AC, Stein EA.

J Am Coll Cardiol. 2012 Jun 19;59(25):2344-53. doi: 10.1016/j.jacc.2012.03.007. Epub 2012 Mar 28.

3.

[In addition to atorvastatin. Innovative antibody lowers LDL around 72%].

Einecke D.

MMW Fortschr Med. 2012 Apr 19;154(7):28. German. No abstract available.

PMID:
22558865
4.

Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial.

Schwartz GG, Bessac L, Berdan LG, Bhatt DL, Bittner V, Diaz R, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Mahaffey KW, Moryusef A, Pordy R, Roe MT, Rorick T, Sasiela WJ, Shirodaria C, Szarek M, Tamby JF, Tricoci P, White H, Zeiher A, Steg PG.

Am Heart J. 2014 Nov;168(5):682-9. doi: 10.1016/j.ahj.2014.07.028. Epub 2014 Aug 7.

5.

Cardiovascular endocrinology in 2012: PCSK9-an exciting target for reducing LDL-cholesterol levels.

Betteridge DJ.

Nat Rev Endocrinol. 2013 Feb;9(2):76-8. doi: 10.1038/nrendo.2012.254. Epub 2013 Jan 8. Review.

PMID:
23296165
6.

Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia.

Roth EM, McKenney JM, Hanotin C, Asset G, Stein EA.

N Engl J Med. 2012 Nov 15;367(20):1891-900. doi: 10.1056/NEJMoa1201832. Epub 2012 Oct 31.

7.

Design and rationale of the LAPLACE-TIMI 57 trial: a phase II, double-blind, placebo-controlled study of the efficacy and tolerability of a monoclonal antibody inhibitor of PCSK9 in subjects with hypercholesterolemia on background statin therapy.

Kohli P, Desai NR, Giugliano RP, Kim JB, Somaratne R, Huang F, Knusel B, McDonald S, Abrahamsen T, Wasserman SM, Scott R, Sabatine MS.

Clin Cardiol. 2012;35(7):385-91. doi: 10.1002/clc.22014. Epub 2012 Jun 19.

8.

Effect of a monoclonal antibody to PCSK9 on LDL cholesterol.

Stein EA, Mellis S, Yancopoulos GD, Stahl N, Logan D, Smith WB, Lisbon E, Gutierrez M, Webb C, Wu R, Du Y, Kranz T, Gasparino E, Swergold GD.

N Engl J Med. 2012 Mar 22;366(12):1108-18. doi: 10.1056/NEJMoa1105803.

9.

Long-term effects of ezetimibe-plus-statin therapy on low-density lipoprotein cholesterol levels as compared with double-dose statin therapy in patients with coronary artery disease.

Okada K, Iwahashi N, Endo T, Himeno H, Fukui K, Kobayashi S, Shimizu M, Iwasawa Y, Morita Y, Wada A, Shigemasa T, Mochida Y, Shimizu T, Sawada R, Uchino K, Umemura S, Kimura K.

Atherosclerosis. 2012 Oct;224(2):454-6. doi: 10.1016/j.atherosclerosis.2012.07.036. Epub 2012 Aug 4.

PMID:
22892323
10.

Into the future: diversifying lipid management.

Tonkin AM, Watts GF.

Lancet. 2012 Dec 8;380(9858):1971-4. doi: 10.1016/S0140-6736(12)61888-1. Epub 2012 Nov 6. No abstract available.

PMID:
23141810
11.

New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.

Sahebkar A, Watts GF.

Clin Ther. 2013 Aug;35(8):1082-98. doi: 10.1016/j.clinthera.2013.06.019. Epub 2013 Aug 8. Review.

PMID:
23932550
12.

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors for Treatment of High Cholesterol Levels: Effectiveness and Value.

Tice JA, Kazi DS, Pearson SD.

JAMA Intern Med. 2016 Jan;176(1):107-8. doi: 10.1001/jamainternmed.2015.7248. Review. No abstract available.

13.

Reducing LDL with PCSK9 Inhibitors--The Clinical Benefit of Lipid Drugs.

Everett BM, Smith RJ, Hiatt WR.

N Engl J Med. 2015 Oct 22;373(17):1588-91. doi: 10.1056/NEJMp1508120. Epub 2015 Oct 7. No abstract available.

14.

The potential role of anti-PCSK9 monoclonal antibodies in the management of hypercholesterolemia.

Lepor NE, Contreras L, Desai C, Kereiakes DJ.

Rev Cardiovasc Med. 2014;15(4):290-307; quiz 308-9. Review.

PMID:
25662924
15.

How far down to push the LDL cholesterol? PCSK9 where statins fail.

Simko V, Ginter E.

Bratisl Lek Listy. 2016;117(4):193-4. No abstract available.

PMID:
27075380
16.

Circulating proprotein convertase subtilisin kexin type 9 has a diurnal rhythm synchronous with cholesterol synthesis and is reduced by fasting in humans.

Persson L, Cao G, Ståhle L, Sjöberg BG, Troutt JS, Konrad RJ, Gälman C, Wallén H, Eriksson M, Hafström I, Lind S, Dahlin M, Amark P, Angelin B, Rudling M.

Arterioscler Thromb Vasc Biol. 2010 Dec;30(12):2666-72. doi: 10.1161/ATVBAHA.110.214130. Epub 2010 Sep 30.

18.

Alirocumab (Praluent) to lower LDL-Cholesterol.

[No authors listed]

Med Lett Drugs Ther. 2015 Aug 17;57(1475):113-5. Review. No abstract available.

PMID:
26262881
19.

[Antibodies in addition to statin therapy lowers LDL cholesterol].

Bossenmayer S.

Dtsch Med Wochenschr. 2012 Sep;137(36):1728. German. No abstract available.

PMID:
23281534
20.

High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol.

Welder G, Zineh I, Pacanowski MA, Troutt JS, Cao G, Konrad RJ.

J Lipid Res. 2010 Sep;51(9):2714-21. doi: 10.1194/jlr.M008144. Epub 2010 Jun 5.

Supplemental Content

Support Center